A carregar...
Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses
Upadacitinib is a selective Janus kinase 1 inhibitor that was recently approved for treatment of rheumatoid arthritis and is currently being evaluated for treatment of several other autoimmune diseases, including atopic dermatitis (AD). The relationships between upadacitinib plasma exposure and effi...
Na minha lista:
| Publicado no: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049015/ https://ncbi.nlm.nih.gov/pubmed/33156550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1782 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|